Serum β-synuclein

Biomarker

2 papers study it1 more mentions it7 findings

Humans2

Upstream

Alzheimer's disease

upin humans1

1 study

Alzheimer's disease increases serum β-synuclein in humans.
“Serum β‐synuclein levels were significantly elevated in AD patients and those with mild cognitive impairment (MCI) compared to cognitively normal (CN) individuals.”
HumansAD patients and MCI vs CNserum
Serum β‐Synuclein as a Potential Early Biomarker for Alzheimer's Disease
AAIC 2025 abstractDec 25, 2025

Associations

Alzheimer's disease

upin humans2

2 studies

Alzheimer's disease is associated with serum β-synuclein in humans (Cohen's d = 0.69 versus controls).
“Serum β-synuclein was selectively elevated in the Alzheimer's disease group (Cohen's d = 0.69 vs controls, P < 0.001)”
HumansAlzheimer's disease group versus A-T1- controls
Blood protein linked to dementia risk beyond key markers
Brain : a journal of neurologyOct 21, 2026
Serum β-synuclein predicts Alzheimer's disease in humans (AUC 0.842).
“Serum β‐synuclein differentiated AD from CN with an area under the curve (AUC) of 0.842”
HumansAD vs CNserum
Serum β‐Synuclein as a Potential Early Biomarker for Alzheimer's Disease
AAIC 2025 abstractDec 25, 2025

More on Alzheimer's disease

Bilateral temporal lobe volume

downin humans1

1 study

Serum β-synuclein is associated with bilateral temporal lobe volume in humans (5.0–8.9% unique variance beyond CSF biomarkers).
“Serum β-synuclein was associated with lower bilateral temporal lobe volume-the only lobar regions to survive hierarchical testing”
HumansNon-demented individuals with subjective or mild cognitive impairmentTemporal loben = 137
Blood protein linked to dementia risk beyond key markers
Brain : a journal of neurologyOct 21, 2026

Mortality

upin humans1HR 1.33

1 study

Serum β-synuclein predicts mortality in humans (HR 1.33, 95% CI 1.07–1.65 per SD increase).
“higher mortality (HR = 1.33; 95% CI: 1.07, 1.65; P = 0.010)”
HumansNon-demented individuals with subjective or mild cognitive impairment; per standard deviation increase in serum β-synucleinMedian follow-up 7.0 yearsn = 258
Blood protein linked to dementia risk beyond key markers
Brain : a journal of neurologyOct 21, 2026

Cognitive function

downin humans1

1 study

Serum β-synuclein predicts cognitive function in humans (-0.11 SD/year, 95% CI -0.18 to -0.04; corresponding to -0.20 MMSE points/year).
“faster cognitive decline (-0.11 SD/year, 95% CI: -0.18, -0.04, P = 0.002, corresponding to -0.20 MMSE points/year)”
HumansNon-demented individuals with subjective or mild cognitive impairment; per standard deviation increase in serum β-synucleinn = 185
Blood protein linked to dementia risk beyond key markers
Brain : a journal of neurologyOct 21, 2026

Dementia conversion

upin humans1HR 1.4

1 study

Serum β-synuclein predicts dementia conversion in humans (HR 1.40, 95% CI 1.11–1.77 per SD increase).
“Each standard deviation increase was associated with higher risk of dementia conversion (hazard ratio (HR) = 1.40; 95% CI: 1.11, 1.77; P = 0.005)”
HumansNon-demented individuals with subjective or mild cognitive impairment; per standard deviation increase in serum β-synucleinMedian follow-up 4.1 yearsn = 185
Blood protein linked to dementia risk beyond key markers
Brain : a journal of neurologyOct 21, 2026

Latest

3 papers in 12 months

BrainOct 22

Blood protein linked to dementia risk beyond key markers

An observational study of 259 people with cognitive difficulties linked higher blood protein levels to later dementia and death beyond some established Alzheimer’s…An observational study of 259 people with cognitive difficulties linked higher blood protein levels to later dementia and death beyond some established Alzheimer’s markers.

Cohort · 185 peopleDementia